在老化中的Apolipoprotein E4小鼠中抑制胆固醇储存酶ACAT1/SOAT1会改变它们的大脑炎症概况
bioRxiv : the preprint server for biology
|November 1, 2024
概括
一个针对胆固醇和神经炎症的新型纳米粒子显示出治疗阿尔茨海默病的前景. 这种方法可以降低APOE4小鼠的关键炎症标志物,这表明阿尔茨海默病晚发症的潜在治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 衰老和Apolipoprotein E4 (APOE4) 是晚发性阿尔茨海默病 (LOAD) 的主要危险因素.
- 与APOE3.3不同的是,APOE4会破坏胆固醇平衡,并加剧神经炎症.
- 针对胆固醇 (CE) 和神经炎症,为APOE4相关的表型提供了潜在的治疗途径.
研究的目的:
- 研究通过纳米颗粒传递的ACAT抑制剂F12511在改善APOE4依赖的LOAD表型方面的疗效.
- 评估F12511对胆固醇代谢,神经炎症和APOE4微质和大脑中的Toll-like受体4 (TLR4) 信号的影响.
主要方法:
- 来自APOE4小鼠的初级微质被用F12511治疗,以评估对CE,ABCA1激活和NFkB信号传递的影响.
- 年龄较大的雌性APOE4小鼠在两周内接受了纳米粒子F12511注射.
- 脑组织分析的重点是TLR4蛋白水平和益炎性细胞因子 (例如IL-1β) 度.
主要成果:
- 在APOE4微质中,F12511治疗降低了CE和激活胆固醇外流 (ABCA1).
- F12511在APOE4微质中受化脂多糖 (LPS) 诱导的NFkB激活.
- 在体内,纳米粒子F12511降低了老年APOE4小鼠的大脑TLR4蛋白和IL-1β水平.
结论:
- 纳米粒子输送的F12511在APOE4小鼠模型中有效降低胆固醇和神经炎症.
- 这种方法调节与LOAD相关的TLR4信号和炎症通路.
- 纳米粒子F12511代表了一种有前途的新型治疗剂,用于改善LOAD.
更多相关视频
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
8.2K
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.1K
相关概念视频
Inflammation
46.6K
Overview
46.6K
Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
